Understanding and Treating Treatment-Resistant Depression: Medications and Non-Pharmacological Options

Dr. Tracey Marks defines Treatment-Resistant Depression (TRD) as experiencing two failed 6-week antidepressant trials, emphasizing the crucial caveats of taking medication at a minimally therapeutic dose and distinguishing between full non-response and partial improvement. She clarifies that stopping medication due to intolerable side effects does not constitute a failed trial. A significant portion of TRD cases, estimated at 40-60%, may actually be misdiagnosed bipolar disorder, highlighting the importance of accurate diagnosis. Additionally, underlying medical conditions such as hypothyroidism, chronic pain, low testosterone, inflammatory illnesses, and sleep apnea can impede depression recovery, necessitating a comprehensive medical evaluation.

The podcast delves into various treatment options, starting with medication augmentation strategies. Atypical antipsychotics like Abilify, Seroquel, Zyprexa, and Rexulti are discussed, with specific FDA approvals and common side effects such as akathisia (restlessness) and significant weight gain. Risperidone is mentioned for its off-label use based on research. Lithium, primarily used for bipolar disorder, is presented as a powerful augmentative agent for TRD, notably reducing suicide risk fivefold for unipolar depression and sixfold for bipolar depression, though it requires blood monitoring and carries risks of kidney and thyroid issues. Thyroid hormone, particularly T3 agents like Cytomel, is also suggested, especially for individuals with low-normal thyroid levels that can exacerbate psychiatric conditions.

Beyond these, Dr. Marks briefly lists other options including Mirtazapine, Mirapex (pramipexole), L-methylfolate, and the over-the-counter supplement SAMe. The ultimate goal of treatment is to achieve remission, where symptoms resolve and the individual returns to their baseline functioning. Once remission is sustained for three to six months, a slow tapering off of the added medication can be considered, acknowledging that unipolar depression is a recurring illness that can cycle.

For individuals who cannot tolerate medications or find them ineffective, two non-medication options are presented: Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS). ECT is highlighted as the most effective treatment available, next to clozapine, despite its association with memory problems and the need for general anesthesia. TMS, developed to mitigate memory loss, is a less invasive but also less effective option, requiring a more significant time commitment with daily treatments over several weeks. The discussion underscores the necessity of a personalized and persistent approach to managing TRD, considering both pharmacological and non-pharmacological interventions while carefully weighing their benefits and drawbacks.

"treatment-resistant depression is defined as having two failed 6-week antidepressant trials"

"when you take the medication you need to take it at a minimally therapeutic dose for six weeks"

"if you've tried three or four antidepressants and had to stop because of side effects this doesn't mean that you're treatment resistant"

"I call it treatment resistant when a person only gets partially better and then the part that's left over still makes them pretty dysfunctional"

"forty to sixty percent of cases of treatment resistant depression are really bipolar disorder"

"the atypical antipsychotic medications have been the most studied to be shown to be useful"

"lithium reduced the risk of suicide fivefold for unipolar depression and six-fold for bipolar depression"

"ECT is still the best treatment that we have next to clozapine"

"TMS was developed to overcome this issue of memory loss and it stimulates the brain I'm using technology that's similar to an MRI"

"the goal here is to get you into remission where you're back to your baseline then you stay in remission for three to six months before slowly tapering off this added medication"